AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 145 filers reported holding AERIE PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 1.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $592,000 | +49.9% | 78,879 | +81.5% | 0.00% | – |
| Q1 2022 | $395,000 | +50.2% | 43,456 | +16.0% | 0.00% | – |
| Q4 2021 | $263,000 | -72.1% | 37,468 | -54.7% | 0.00% | -100.0% |
| Q3 2021 | $943,000 | -11.2% | 82,760 | +24.8% | 0.00% | 0.0% |
| Q2 2021 | $1,062,000 | -15.6% | 66,337 | -5.8% | 0.00% | 0.0% |
| Q1 2021 | $1,259,000 | +47.9% | 70,439 | +11.8% | 0.00% | 0.0% |
| Q4 2020 | $851,000 | +33.2% | 62,978 | +16.1% | 0.00% | 0.0% |
| Q3 2020 | $639,000 | +46.9% | 54,255 | +84.1% | 0.00% | – |
| Q2 2020 | $435,000 | +133.9% | 29,465 | +113.6% | 0.00% | – |
| Q1 2020 | $186,000 | -18.1% | 13,792 | +47.1% | 0.00% | – |
| Q4 2019 | $227,000 | +931.8% | 9,376 | +2164.7% | 0.00% | – |
| Q2 2017 | $22,000 | +15.8% | 414 | 0.0% | 0.00% | – |
| Q1 2017 | $19,000 | +18.8% | 414 | 0.0% | 0.00% | – |
| Q4 2016 | $16,000 | – | 414 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 805,217 | $14,212,000 | 4.99% |
| DAFNA Capital Management LLC | 156,842 | $2,768,000 | 2.34% |
| NORTHPOINTE CAPITAL LLC | 1,034,400 | $18,257,000 | 2.15% |
| HARVEY CAPITAL MANAGEMENT INC | 223,200 | $3,856,000 | 1.30% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,211,644 | $39,036,000 | 1.30% |
| Boulegeris Investments, Inc. | 88,660 | $1,565,000 | 1.12% |
| Partner Investment Management, L.P. | 43,623 | $770,000 | 1.08% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 150,000 | $2,648,000 | 0.92% |
| PFM Health Sciences, LP | 1,851,564 | $32,680,000 | 0.83% |
| Benchmark Capital Advisors | 55,400 | $978,000 | 0.69% |